Pharmacogenetics of Angiogenesis
Authors:
- Guido BocciGBGuido Bocci
- Giuseppe PasqualettiGPGiuseppe Pasqualetti
- Antonello Di PaoloAPAntonello Di Paolo
- Francesco CreaFCFrancesco Crea
- Mario Del TaccaMTMario Del Tacca
- Romano DanesiRDRomano Danesi
- 3 August 2010
- book chapter
- Published by Springer Nature
- p. 233-242
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor TherapyClinical Cancer Research, 2008
- Polymorphisms in Angiogenesis-Related Genes and Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate CancerClinical Cancer Research, 2008
- A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIVBritish Journal of Cancer, 2007
- Role of MMP-1 1G/2G Promoter Gene Polymorphism on the Development of Prostate Cancer in the Turkish PopulationUrologia Internationalis, 2007
- Hypoxia‐inducible factor‐1α (HIF‐1α) gene polymorphisms, circulating insulin‐like growth factor binding protein (IGFBP)‐3 levels and prostate cancerThe Prostate, 2007
- Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)Investigational New Drugs, 2007
- Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor ReceptorCancer Research, 2007
- Lenalidomide in Myelodysplastic Syndrome and Multiple MyelomaDrugs, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006